RCD news
Iteria Biopharma closes an EUR 5M funding round for the development of its prostate cancer drug
Iteria Biopharma, which specialises in the development of new drugs for advanced metastatic cancers, has closed a EUR 5M funding round
The new funds will enable the biotech company to complete the regulatory preclinical development of its drug for metastatic prostate cancer and commence its first clinical trial, as well as to advance other projects in pancreatic, colorectal, and lung cancer.
A team led by David Pintos has advised Iteria Biopharma on this transaction.
